Introduction – The first phase of the OPTIMISE study is a four-week treatment of first-episode psychotic patients with amisulpride. 
Objectives – The aim was to assess extrapyramidal and depressive symptoms in these patients before and after amisulpride treatment.  
Methods - The study involved 441 patients, 311 male, aged 25.2+5.2 years and 130 female, aged 26.9+6.6 years, with a previous use of antipsychotic drugs of less than 2 weeks during the preceding year and less than 6 weeks lifetime. Extrapyramidal symptoms were assessed by the UKU Side Effect Rating Scale and depressive symptoms were estimated by the Calgary Depression Scale for Schizophrenia (CDSS).
Results – In 251(66,8%) patients, the response to treatment was noted. At baseline, the frequency of extrapyramidal symptoms was: akathisia 14.5%; tremor 14.3%; akinesia 11.3%; rigidity 11.1%, dystonia 9.5%; hyperkinesia 3.9%. Some of them were more marked in women. There were no significant changes after amisulpride in responders to treatment, however, in non-responders, the frequency of akathisia, tremor, akinesia and rigidity significantly increased. The mean CDSS score at baseline was 4.5+4.6, correlated with the intensity of most extrapyramidal symptoms, and significantly decreased after treatment (2.8+3.8), more so in responders than in non-responders.  
Conclusions - The results suggest the relatively high intensity of extrapyramidal and depressive symptoms before treatment in these patients. After treatment in responders, no change in frequency of extrapyramidal symptoms and significant decrease of depressive symptoms was noted. In non-responders, there was an increase in extrapyramidal and less decrease of depressive symptoms.

09 - EXTRAPYRAMIDAL AND DEPRESSIVE SYMPTOMS IN FIRST-EPISODE PSYCHOSIS DURING AMISULPRIDE TREATMENT- THE RESULTS OF OPTIMISE STUDY